Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients

• Published in: Diabetes research and clinical practice Vol. 77; no. 2; pp. 210 - 214
• Main Authors: Usui, Isao, Fujisaka, Shiho, Yamazaki, Katsuya, Takano, Atsuko, Murakami, Shiho, Yamazaki, Yu, Urakaze, Masaharu, Hachiya, Haruo, Takata, Michiyo, Senda, Satoko, Iwata, Minoru, Satoh, Akira, Sasaoka, Toshiyasu, AK, Norel Dim, Temaru, Rie, Kobayashi, Masashi
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 01-08-2007
• Subjects: Adiponectin - blood; Adult; Aged; Aged, 80 and over; Albuminuria - prevention & control; Angiotensin II Type 1 Receptor Blockers - therapeutic use; ARB; Benzimidazoles - therapeutic use; Benzoates - therapeutic use; Blood Pressure - drug effects; Body Mass Index; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - physiopathology; Diabetic Angiopathies - drug therapy; Diet, Diabetic; Endocrinology & Metabolism; Female; HOMA-IR; Humans; Hypertension - drug therapy; Hypoglycemic Agents - therapeutic use; Leptin; Leptin - blood; Lipids - blood; Male; Middle Aged; Telmisartan; ARB; HOMA-IR; Leptin; Telmisartan
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2006.11.014

Abstract Telmisartan, a new angiotensin II type 1 receptor blocker (ARB), was recently reported to stimulate PPARγ, and stronger effects of Telmisartan on insulin sensitivity has been expected than the class effect of ARB. In the present study, we examined the effects of Telmisartan on insulin sensitivity and adipokine levels in hypertensive and type 2 diabetic patients. Outpatients with both hypertension and type 2 diabetes mellitus ( n = 36; male 23, female 13), received 20–40 mg Telmisartan orally once daily for 6 months. Physical examinations and blood or urine tests were performed before and 3 or 6 months after starting Telmisartan treatment. Results were statistically compared using Wilcoxon analysis. Telmisartan treatment for 3 or 6 months reduced systolic and diastolic blood pressure and urinary albumin excretion. Fasting plasma glucose, HbA1c, total and HDL-cholesterol, triglyceride, body weight, BMI and waist length were not changed. Fasting IRI and HOMA-IR were significantly decreased after Telmisartan treatment, suggesting the improved insulin sensitivity. Total and high molecular adiponectin were not changed. Interestingly, serum leptin was significantly increased by 3 months Telmisartan treatment, suggesting a possible involvement of leptin in improved insulin sensitivity. In conclusion, Telmisartan improved insulin resistance with increased serum leptin level in hypertensive and type 2 diabetic patients.